PE20001087A1 - Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico - Google Patents

Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico

Info

Publication number: PE20001087A1
Authority: PE; Peru
Prior art keywords: morpholinol; difluorophenyl; dimethyl; alginic acid; formulations including
Prior art date: 1998-09-28

Application number

PE1999000976A

Other languages

English (en)

Spanish (es)

Inventor

Samuel Bruce Balik

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-28

Filing date

1999-09-27

Publication date

2000-10-20

1999-09-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-10-20 Publication of PE20001087A1 publication Critical patent/PE20001087A1/es

Links

239000000203 mixture Substances 0.000 title abstract 3
239000000783 alginic acid Substances 0.000 title abstract 2
235000010443 alginic acid Nutrition 0.000 title abstract 2
229920000615 alginic acid Polymers 0.000 title abstract 2
229960001126 alginic acid Drugs 0.000 title abstract 2
150000004781 alginic acids Chemical class 0.000 title abstract 2
OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 title abstract 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
206010012335 Dependence Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
241000208125 Nicotiana Species 0.000 abstract 1
235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
-1 SACAROSE Chemical compound 0.000 abstract 1
235000021355 Stearic acid Nutrition 0.000 abstract 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
229940049654 glyceryl behenate Drugs 0.000 abstract 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
235000019359 magnesium stearate Nutrition 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
229960002715 nicotine Drugs 0.000 abstract 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940079832 sodium starch glycolate Drugs 0.000 abstract 1
229920003109 sodium starch glycolate Polymers 0.000 abstract 1
239000008109 sodium starch glycolate Substances 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
239000008117 stearic acid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Addiction (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE1999000976A 1998-09-28 1999-09-27 Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico PE20001087A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10211298P	1998-09-28	1998-09-28

Publications (1)

Publication Number	Publication Date
PE20001087A1 true PE20001087A1 (es)	2000-10-20

Family

ID=22288187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1999000976A PE20001087A1 (es)	1998-09-28	1999-09-27	Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico

Country Status (17)

Country	Link
EP (1)	EP1117407A1 (pt)
JP (1)	JP2002525328A (pt)
KR (1)	KR20010075385A (pt)
CN (1)	CN1328459A (pt)
AR (1)	AR022673A1 (pt)
AU (1)	AU6087399A (pt)
BR (1)	BR9914096A (pt)
CA (1)	CA2345638A1 (pt)
CZ (1)	CZ20011142A3 (pt)
HU (1)	HUP0103459A2 (pt)
IL (1)	IL142054A0 (pt)
MA (1)	MA26693A1 (pt)
NO (1)	NO20011555L (pt)
PE (1)	PE20001087A1 (pt)
PL (1)	PL346877A1 (pt)
TR (1)	TR200100863T2 (pt)
WO (1)	WO2000018406A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7750100A (en) *	1999-10-13	2001-04-23	Glaxo Group Limited	Method for the treatment of obesity
DE102008047910A1 (de)	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4597969A (en) *	1982-04-05	1986-07-01	Merck Sharp & Dohme	Stabilization of unstable drugs or food supplements
GB8924528D0 (en) *	1989-10-31	1989-12-20	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use

1999
- 1999-09-23 MA MA25782A patent/MA26693A1/fr unknown
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/xx unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/xx unknown
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/ko not_active Withdrawn
- 1999-09-24 PL PL99346877A patent/PL346877A1/xx unknown
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/hu unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/pt not_active IP Right Cessation
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/ja active Pending
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 CN CN99813675A patent/CN1328459A/zh active Pending
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Ceased
- 1999-09-24 AR ARP990104841A patent/AR022673A1/es unknown
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/cs unknown
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/es not_active Application Discontinuation
2001
- 2001-03-27 NO NO20011555A patent/NO20011555L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20011555D0 (no)	2001-03-27
CA2345638A1 (en)	2000-04-06
KR20010075385A (ko)	2001-08-09
MA26693A1 (fr)	2004-12-20
IL142054A0 (en)	2002-03-10
PL346877A1 (en)	2002-03-11
AR022673A1 (es)	2002-09-04
CZ20011142A3 (cs)	2001-09-12
EP1117407A1 (en)	2001-07-25
NO20011555L (no)	2001-03-27
AU6087399A (en)	2000-04-17
BR9914096A (pt)	2001-07-31
CN1328459A (zh)	2001-12-26
HUP0103459A2 (hu)	2002-01-28
WO2000018406A1 (en)	2000-04-06
TR200100863T2 (tr)	2001-07-23
JP2002525328A (ja)	2002-08-13

Similar Documents

Publication	Publication Date	Title
MX9207169A (es)	1994-06-30	Composiciones orales para suprimir olores bucales.
CY1106634T1 (el)	2012-01-25	Θεραπευτικα παραγωγα της πιπεραζινης
UY24308A1 (es)	1996-08-27	Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
GR3031135T3 (en)	1999-12-31	Compositions containing S(+)-Ibuprofen.
YU23599A (sh)	2001-07-10	Stabilizovani antihistaminski sirup
KR890011592A (ko)	1989-08-21	기관내 허혈병의 치료용 조성물
BR9810312A (pt)	2000-09-19	Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
FI943315A0 (fi)	1994-07-12	Farmaseuttinen valmiste pore- ja/tai hajoamistabletin tai pikarakeiden muodossa, samoin kuin menetelmä valmistaa niitä
ES2063093T3 (es)	1995-01-01	Composiciones orales.
AU6593301A (en)	2001-12-11	Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
EP1222922A4 (en)	2006-04-12	METHOD FOR STABILIZING BENZIMIDAZOLE COMPOUNDS
RU94044456A (ru)	1996-10-10	Средство для подавления дисфункционального маточного кровотечения
BR8400234A (pt)	1984-08-28	Compostos de benzoilureia,processo para a preparacao de compostos de benzoilureia,composicao tendo atividade inseticida e acaricida,composicao farmaceutica,processo para preparacao de uma composicao tendo atividade inseticida e acaricida,processo para controlar insetos e/ou acaros e processo para combater tumores em seres vivos
DE69031340D1 (de)	1997-10-02	3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
ES2087623T3 (es)	1996-07-16	Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
EP1123701A4 (en)	2003-07-16	NATURAL PHYSIOLOGICALLY ACTIVE SUBSTANCES THAT ARE EFFECTIVE AGAINST FISH DISEASES AND FISH FOOD CONTAINING THEM
BR0311642A (pt)	2005-03-01	Formulação de divalproex de sódio de liberação aumentada
PE20001087A1 (es)	2000-10-20	Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico
PT913151E (pt)	2002-11-29	Composicoes de luta contra a helicobacter pylori que contem derivados de 1-metilcarbapenem como substancia activa
ES475533A1 (es)	1980-01-16	Un metodo para la preparacion de formas racemicas y optica- mente activas de 2-(4-difenilil)-n-(dimetilamino-alquil)pro-pionamida
ES2123808T3 (es)	1999-01-16	Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.
ES2113136T3 (es)	1998-04-16	Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion.
ES2067206T3 (es)	1995-03-16	Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria.
SE9900190D0 (sv)	1999-01-22	New compounds
CA2345364A1 (fr)	2000-04-13	Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries

Legal Events

Date	Code	Title	Description
2003-04-16	FD	Application declared void or lapsed